PT Kimia Farma Tbk (KAEF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Business description - A detailed description of the company’s operations and business divisions.
Corporate strategy - Analyst’s summarization of the company’s business strategy.
SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
Company history - Progression of key events associated with the company.
Major products and services - A list of major products, services and brands of the company.
Key competitors - A list of key competitors to the company.
Key employees - A list of the key executives of the company.
Executive biographies - A brief summary of the executives’ employment history.
Key operational heads - A list of personnel heading key departments/functions.
Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
PT Kimia Farma Tbk (Kimia Farma), a subsidiary of PT Bio Farma, is a pharmaceutical company that manufactures, commercializes, and distributes pharmaceutical products. The company's products include finished drugs, herbal medicines, and cosmetics. It offers products in various categories, including the alimentary system, allergy and immune system, anaesthetics (both local and general), antibiotics, antidotes, and detoxifying agents. Additional categories include cardiovascular and hematopoietic, dermatological, eye and ear, genito-urinary system, hormones, intravenous and other sterile products, metabolism, neuromuscular treatments, other chemotherapeutics, respiratory aids, vitamins, and minerals. Kimia Farma operates a distribution network that supplies its products to pharmacies, hospitals, and medical centers in Asia, Europe, and Africa. The company operates manufacturing plants in Jakarta, Bandung, Semarang, Watudakon, Medan, and West Java, among others. Kimia Farma is headquartered in Jakarta, Indonesia.
PT Kimia Farma Tbk Key Recent Developments
Apr 06, 2026: PT Kimia Farma Launches Stemxera and Expands Biotechnology Collaboration
Dec 30, 2025: EGMS Approves Transfer of PT Kimia Farma Tbk Assets
Oct 16, 2025: PT Kimia Farma Tbk is Collaborating on Export Distribution with Soidal Medical Supplies Ltd Papua New Guinea
Oct 13, 2025: KIMIA FARMA, in Collaboration with RSCM, Expands Stem Cell Therapy Services
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Section 1 - About the Company
Biocon Ltd - Key Facts
Biocon Ltd - Key Employees
Biocon Ltd - Key Employee Biographies
Biocon Ltd - Major Products and Services
Biocon Ltd - History
Biocon Ltd - Company Statement
Biocon Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 - Company Analysis
Company Overview
Biocon Ltd - Business Description
Business Segment: Biosimilars
Overview
Performance
Business Segment: Generics
Overview
Performance
Business Segment: Research Services
Overview
Performance
Geographical Segment: European Union (including Ireland)
Performance
Geographical Segment: India
Performance
Geographical Segment: Rest of the World
Performance
Geographical Segment: United States of America
Performance
R&D Overview
Biocon Ltd - Corporate Strategy
Biocon Ltd - SWOT Analysis
SWOT Analysis - Overview
Biocon Ltd - Strengths
Biocon Ltd - Weaknesses
Biocon Ltd - Opportunities
Biocon Ltd - Threats
Biocon Ltd - Key Competitors
Section 3 - Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences, Power Financial Deals and Alliances
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
Biocon Ltd, Recent Deals Summary
Section 5 - Company’s Recent Developments
Jul 29, 2026: Biocon Receives Health Canada Approval for Yesintek® (ustekinumab) Autoinjector Pen
Jul 28, 2026: Biocon Foundation and IISc Convene National Experts to Shape India’s Oral Cancer Elimination Strategy
Jul 21, 2026: Biocon Limited partners with Tabuk Pharmaceuticals to commercialise its Glucagon-like peptide-1 (GLP-1) products in the Middle East region
Jul 21, 2026: Biocon Announces Mr. Bobby Kanubhai Parikh Has Completed Independent Director and Consequently Ceased to Be a Director of the Company
Jun 24, 2026: Biocon Reinforces Commitment to Diabetes Care in Malaysia as Duopharma Biotech Secures Insulin Tenders
May 07, 2026: Biocon Reports Q4 FY26 Total Income and EBITDA, and FY26 Financial Results
Apr 30, 2026: U.S. FDA Completes Pre-License Inspection at Biocon’s Biosimilars Site at Biocon Park, Bengaluru, India
Apr 28, 2026: Toyota Mobility Foundation, Biocon, and WRI India Launch Commute Nudge Program to Promote Public Transport
Apr 22, 2026: Health Canada approves Biocon’s two denosumab biosimilars
Mar 27, 2026: Shreehas Tambe Appointed CEO & Managing Director of Biocon Limited, Effective April 1, 2026
Section 6 - Appendix
Methodology
Ratio Definitions
About the Analyst
Contact the Publisher
Disclaimer
List of Tables
Biocon Ltd, Key Facts
Biocon Ltd, Key Employees
Biocon Ltd, Key Employee Biographies
Biocon Ltd, Major Products and Services
Biocon Ltd, History
Biocon Ltd, Other Locations
Biocon Ltd, Subsidiaries
Biocon Ltd, Joint Venture
Biocon Ltd, Key Competitors
Biocon Ltd, Ratios based on current share price
Biocon Ltd, Annual Ratios
Biocon Ltd, Interim Ratios
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
Biocon Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Biocon Ltd, Performance Chart (2022 - 2026)
Biocon Ltd, Ratio Charts
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
Biocon Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2020 to YTD 2026
This product is a company SWOT Analysis. Each license type allows a set number of users to access the report. Please select an option from the list below. This product is a company SWOT Analysis. This is a single user license, allowing one user access to the product. The product is a PDF. This product is a company SWOT Analysis. This is a site license, allowing all users within a given geographical location of your organization access to the product. The product is a PDF.
The sample excerpt is provided to help you make an informed purchasing decision. It is not intended to serve as free content or replace a full report. To ensure the sample aligns with your specific needs, our team will contact you to better understand your requirements.
An error occurred while sending the message. Should this issue persist, email us at help@researchandmarkets.net
This report can be tailored to focus on a specific country, region, continent, or provide global coverage. Please indicate your regions of interest and share any additional questions you may have. Our team strives to respond to all inquiries within the same business day.
An error occurred while sending the message. Should this issue persist, email us at help@researchandmarkets.net